Fas/APO-1 (CD95)-mediated apoptosis is activated by interferon-γ and interferon-α in interleukin-6 (IL-6)-dependent and IL-6-independent multiple myeloma cell lines

Blood

Volumn 92, Issue 8, 1998, Pages 2914-2923

  Spets, Helena ^a   Georgii Hemming, Patrik ^a   Siljason, Jan ^a   Nilsson, Kenneth ^a   Jernberg Wiklund, Helena ^a  

^a UPPSALA UNIVERSITY HOSPITAL   (Sweden)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA INTERFERON; FAS ANTIGEN; GAMMA INTERFERON; INTERLEUKIN 6;

ANTIGEN EXPRESSION; APOPTOSIS; ARTICLE; CANCER CELL CULTURE; CELL GROWTH; CELL SURVIVAL; CONTROLLED STUDY; HUMAN; HUMAN CELL; MULTIPLE MYELOMA; PRIORITY JOURNAL;

EID: 0032532290     PISSN: 00064971     EISSN: None     Source Type: Journal    
DOI: 10.1182/blood.v92.8.2914     Document Type: Article

References (56)

1. Kawano M, Hirano T, Matsuda T, Taga T, Horii Y, Iwato K, Asaoku H, Tang B, Tanabe O, Tanaka H, Kuramoto A, Kishimoto T: Autocrine generation and requirement of BSF-2/IL-6 for human multiple myelomas. Nature 332:83, 1988
2. Klein B, Zhang XG, Jourdan M, Content J, Houssiau F, Aarden L, Piechaczyk M, Bataille R: Paracrine rather than autocrine regulation of myeloma-cell growth and differentiation by interleukin-6. Blood 73: 517, 1989
3. Jernberg H, Pettersson M, Kishimoto T, Nilsson K: Heterogeneity in response to interleukin 6 (IL-6), expression of IL-6 and IL-6 receptor mRNA in a panel of established human multiple myeloma cell lines. Leukemia 5:255, 1991 (erratum 5:530, 1991)
4. Spets H, Jernberg Wiklund H, Sambade C, Soderberg O, Nilsson K: The effects on growth and survival of IL-6 can be dissociated in the U-266-1970/U-266-1984 and HL407E/HL407L human multiple myeloma cell lines. Br J Haematol 98: 126, 1997
5. Georgii Hemming P, Wiklund HJ, Ljunggren O, Nilsson K: Insulin-like growth factor I is a growth and survival factor in human multiple myeloma cell lines. Blood 88:2250, 1996
6. Jelinek DF, Witzig TE, Arendt BK: A role for insulin-like growth factor in the regulation of IL-6-responsive human myeloma cell line growth. J Immunol 159:487, 1997
7. Pettersson M, Jernberg Wiklund H, Larsson LG, Sundstrom C, Givol I, Tsujimoto Y, Nilsson K: Expression of the bcl-2 gene in human multiple myeloma cell lines and normal plasma cells. Blood 79:495, 1992
8. Mellstedt H, Ahre A, Bjorkholm M, Holm G, Johansson B, Strander H: Interferon therapy in myelomatosis. Lancet 1:245, 1979
9. Idestrom K, Cantell K, Killander D, Nilsson K, Strander H, Willems J: Interferon therapy in multiple myeloma. Acta Med Scand 205:149, 1979
10. Einhorn S, Strander H: Studies with interferon-alpha in human tumors. Med Oncol Tumor Pharmacother 1:97, 1984
11. Brenning G: The in vitro effect of leucocyte alpha-interferon on human myeloma cells in a semisolid agar culture system. Scand J Haematol 35:178, 1985
12. Brenning G, Jernberg H, Gidlund M, Sjoberg O, Nilsson K: The effect of alpha and gamma-interferon on proliferation and production of IgE and beta 2-microglobulin in the human myeloma cell line U-266 and in an alpha-interferon resistant U-266 subline. Scand J Haematol 37:280, 1986
13. Einhorn S, Fernberg JO, Grander D, Lewensohn R: Interferon exerts a cytotoxic effect on primary human myeloma cells. Eur J Cancer Clin Oncol 24:1505, 1988
14. Peest D, Blade J, Harousseau JL, Klein B, Osterborg A, San Miguel JF: Cytokine therapy in multiple myeloma. Br J Haematol 94:425, 1996
15. Jernberg Wiklund H, Pettersson M, Nilsson K: Recombinant interferon-gamma inhibits the growth of IL-6-dependent human multiple myeloma cell lines in vitro. Eur J Haematol 46:231, 1991
16. Ludwig CU, Durie BG, Salmon SE, Moon TE: Tumor growth stimulation in vitro by interferons. Eur J Cancer Clin Oncol 19:1625, 1983
17. Jourdan M, Zhang XG, Portier M, Boiron JM, Bataille R, Klein B: IFN-alpha induces autocrine production of IL-6 in myeloma cell lines. J Immunol 147:4402, 1991
18. Egle A, Villunger A, Kos M, Bock G, Gruber J, Auer B, Greil R: Modulation of Apo-1/Fas (CD95)-induced programmed cell death in myeloma cells by interferon-alpha 2. Eur J Immunol 26:3119, 1996
19. Klein B: Cytokine, cytokine receptors, tranduction signals, and oncogenes in human multiple myeloma. Semin Hematol 32:4, 1995
20. Portier M, Zhang XG, Caron E, Lu ZY, Bataille R, Klein B: Gamma-interferon in multiple myeloma: Inhibition of interleukin-6 (IL-6)-dependent myeloma cell growth and downregulation of IL-6-receptor expression in vitro. Blood 81:3076, 1993
21. Schwabe M, Brini AT, Bosco MC, Rubboli F, Egawa M, Zhao J, Princier GL, Kung HF: Disruption by interferon-alpha of an autocrine interleukin-6 growth loop in IL-6-dependent U266 myeloma cells by homologous and heterologous down-regulation of the IL-6 receptor alpha-and beta-chains. J Clin Invest 94:2317, 1994
22. Jelinek DF, Aagaard Tillery KM, Arendt BK, Arora T, Tschumper RC, Westendorf JJ: Differential human multiple myeloma cell line responsiveness to interferon-alpha. Analysis of transcription factor activation and interleukin 6 receptor expression. J Clin Invest 99:447, 1997
23. Yonehara S, Ishii A, Yonehara M: A cell-killing monoclonal antibody (anti-Fas) to a cell surface antigen co-downregulated with the receptor of tumor necrosis factor. J Exp Med 169:1747, 1989
24. Trauth BC, Klas C, Peters AM, Matzku S, Moller P, Falk W, Debatin KM, Krammer PH: Monoclonal antibody-mediated tumor regression by induction of apoptosis. Science 245:301, 1989
25. Owen Schaub LB, Meterissian S, Ford RJ: Fas/APO-1 expression and function on malignant cells of hematologic and nonhepatologic origin. J Immunother 14:234, 1993
26. Leithauser F, Dhein J, Mechtersheimer G, Koretz K, Bruderlein S, Henne C, Schmidt A, Debatin KM, Krammer PH, Moller P: Constitutive and induced expression of APO-1, a new member of the nerve growth factor/tumor necrosis factor receptor superfamily, in normal and neoplastic cells. Lab Invest 69:415, 1993
27. Moller P, Henne C, Leithauser F, Eichelmann A, Schmidt A, Bruderlein S, Dhein J, Krammer PH: Coregulation of the APO-1 antigen with intercellular adhesion molecule-1 (CD54) in tonsillar B cells and coordinate expression in follicular center B cells and in follicle center and mediastinal B-cell lymphomas. Blood 81:2067, 1993
28. Shima Y, Nishimoto N, Ogata A, Fujii Y, Yoshizaki K, Kishimoto T: Myeloma cells express Fas antigen/APO-1 (CD95) but only some are sensitive to anti-Fas antibody resulting in apoptosis. Blood 85:757, 1995
29. Westendorf JJ, Lammert JM, Jelinek DF: Expression and function of Fas (APO-1/CD95) in patient myeloma cells and myeloma cell lines. Blood 85:3566, 1995
30. Hata H, Matsuzaki H, Takeya M, Yoshida M, Sonoki T, Nagasaki A, Kuribayashi N, Kawano F, Takatsuki K: Expression of Fas/Apo-1 (CD95) and apoptosis in tumor cells from patients with plasma cell disorders. Blood 86:1939, 1995
31. Cleveland JL, Ihle JN: Contenders in FasL/TNF death signaling. Cell 81:479, 1995
32. Nagata S, Golstein P: The Fas death factor. Science 267:1449, 1995
33. Nagata S: Apoptosis by death factor. Cell 88:355, 1997
34. Jacobson MD: Apoptosis: Bcl-2-related proteins get connected. Curr Biol 7:R277, 1997
35. Selleri C, Sato T, Del Vecchio L, Luciano L, Barrett AJ, Rotoli B, Young NS, Maciejewski JP: Involvement of Fas-mediated apoptosis in the inhibitory effects of interferon-alpha in chronic myelogenous leukemia. Blood 89:957, 1997
36. Nilsson K, Bennich H, Johansson SG, Ponten J: Established immunoglobulin producing myeloma (IgE) and lymphoblastoid (IgG) cell lines from an IgE myeloma patient. Clin Exp Immunol 7:477, 1970
37. Jernberg Wiklund H, Pettersson M, Carlsson M, Nilsson K: Increase in interleukin 6 (IL-6) and IL-6 receptor expression in a human multiple myeloma cell line, U-266, during long-term in vitro culture and the development of a possible autocrine IL-6 loop. Leukemia 6:310, 1992
38. Jernberg H, Nilsson K, Zech L, Lutz D, Nowotny H, Scheirer W: Establishment and phenotypic characterization of three new human myeloma cell lines (U-1957, U-1958, and U-1996). Blood 69:1605, 1987
39. Cory S: Regulation of lymphocyte survival by the bcl-2 gene family. Annu Rev Immunol 13:513, 1995
40. Garrone P, Neidhardt EM, Garcia E, Galibert L, van Kooten C, Banchereau J: Fas ligation induces apoptosis of CD40-activated human B lymphocytes. J Exp Med 182:1265, 1995
41. Miyawaki T, Uehara T, Nibu R, Tsuji T, Yachie A, Yonehara S, Taniguchi N: Differential expression of apoptosis-related Fas antigen on lymphocyte subpopulations in human peripheral blood. J Immunol 149:3753, 1992
42. Daniel PT, Krammer PH: Activation induces sensitivity toward APO-1 (CD95)-mediated apoptosis in human B cells. J Immunol 152:5624, 1994
43. Foote LC, Howard RG, Marshak Rothstein A, Rothstein TL: IL-4 induces Fas resistance in B cells. J Immunol 157:2749, 1996
44. Moller P, Henne C, Leithauser F, Eichelmann A, Schmidt A, Bruderlein S, Dhein J, Krammer PH: Coregulation of the APO-1 antigen with intercellular adhesion molecule-1 (CD54) in tonsillar B cells and coordinate expression in follicular center B cells and in follicle center and mediastinal B-cell lymphomas. Blood 81:2067, 1993
45. Sangfelt O, Erickson S, Einhorn S, Grander D: Induction of Cip/Kip and Ink4 cyclin dependent kinase inhibitors by interferon-alpha in hematopoietic cell lines. Oncogene 14:415, 1997
46. Pellat Deceunynk C, Amiot M, Bataille R, Van Riet I, Van Camp B, Omede P, Boccadoro M: Human myeloma cell lines as a tool for studying the biology of multiple myeloma: A reappraisal 18 years after [letter]. Blood 86:4001, 1995
47. Darzynkiewicz Z, Bruno S, Del Bino G, Gorczyca W, Hotz MA, Lassota P, Traganos F: Features of apoptotic cells measured by flow cytometry. Cytometry 13:795, 1992
48. Majno G, Joris I: Apoptosis, oncosis, and necrosis. An overview of cell death [see comments]. Am J Pathol 146:3, 1995
49. Galibert L, Burdin N, de Saint Vis B, Garrone P, Van Kooten C, Banchereau J, Rousset F: CD40 and B cell antigen receptor dual triggering of resting B lymphocytes turns on a partial germinal center phenotype. J Exp Med 183:77, 1996
50. Panayiotidis P, Ganeshaguru K, Foroni L, Hoffbrand AV: Expression and function of the FAS antigen in B chronic lymphocytic leukemia and hairy cell leukemia. Leukemia 9:1227, 1995
51. Keane MM, Ettenberg SA, Lowrey GA, Russell EK, Lipkowitz S: Fas expression and function in normal and malignant breast cell lines. Cancer Res 56:4791, 1996
52. Ossina NK, Cannas A, Powers VC, Fitzpatrick PA, Knight JD, Gilbert JR, Shekhtman EM, Tomei LD, Umansky SR, Kiefer MC: Interferon-gamma modulates a p53-independent apoptotic pathway and apoptosis-related gene expression. J Biol Chem 272:16351, 1997
53. Armstrong RC, Aja T, Xiang J, Gaur S, Krebs JF, Hoang K, Bai X, Korsmeyer SJ, Karanewsky DS, Fritz LC, Tomaselli KJ: Fasinduced activation of the cell death-related protease CPP32 Is inhibited by Bcl-2 and by ICE family protease inhibitors. J Biol Chem 271: 16850, 1996
54. Oltvai ZN, Milliman CL, Korsmeyer SJ: Bcl-2 heterodimerizes in vivo with a conserved homolog, Bax, that accelerates programmed cell death. Cell 74:609, 1993
55. Orth K, Dixit VM: Bik and Bak induce apoptosis downstream of CrmA but upstream of inhibitor of apoptosis. J Biol Chem 272:8841, 1997
56. Chauhan D, Kharbanda S, Ogata A, Urashima M, Teoh G, Robertson M, Kufe DW, Anderson KC: Interleukin-6 inhibits Fas-induced apoptosis and stress-activated protein kinase activation in multiple myeloma cells. Blood 89:227, 1997